Sesame Immunotherapy: A Systematic Review and Narrative Synthesis. (PubMed, Clin Transl Allergy) - Sep 30, 2026 - "Most adverse events were mild to moderate; severe reactions requiring epinephrine were uncommon, and no deaths were reported. Adjunctive omalizumab improved tolerability in high-risk adults...Randomized controlled trials are needed to define optimal protocols and long-term outcomes. TRAIL REGISTRATION: The protocol for this systematic review was prospectively registered in PROSPERO (International Prospective Register of Systematic Reviews; Registration number: CRD420251087250)."
Journal • Review • Allergy • Food Hypersensitivity • Immunology • Pediatrics
|
|
Katarzyna Grzela; Katarzyna Kunkiel; Marek Kulus
|